Corticosteroid dependent and independent effects of a cannabinoid agonist on core temperature, motor activity, and prepulse inhibition of the acoustic startle reflex in Wistar rats

Psychopharmacology

Volumn 220, Issue 2, 2012, Pages 405-415

  Avdesh, Avdesh ^b   Cornelisse, Vincent ^a   Martin Iverson, Mathew Thomas ^a,b  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Cannabinoid agonist; CB1 receptor; Corticosteroid; CP55940; Metyrapone; Prepulse inhibition; Startle reflex

Indexed keywords

4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; CORTICOSTEROID; METYRAPONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANNABIS ADDICTION; CONTROLLED STUDY; CORE TEMPERATURE; CORTICOSTEROID RELEASE; DRUG DEPENDENCE; HYPOTHERMIA; MALE; MOTOR ACTIVITY; MOTOR DYSFUNCTION; NONHUMAN; PREPULSE INHIBITION; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA; SENSORY GATING; STARTLE REFLEX;

ANIMALS; BODY TEMPERATURE; CYCLOHEXANOLS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ENZYME INHIBITORS; INHIBITION (PSYCHOLOGY); MALE; METYRAPONE; MOTOR ACTIVITY; RATS; RATS, WISTAR; RECEPTORS, CANNABINOID; STARTLE REACTION;

EID: 84858444568     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-011-2493-z     Document Type: Article

References (74)

1. Allebeck P, Adamsson C, Engstrom A, Rydberg U (1993) Cannabis and schizophrenia: a longitudinal study of cases treated in Stockholm County. Acta Psychiatr Scand 88:21-24 (Pubitemid 23199896)
2. Andreasson S, Allebeck P, Engstrom A, Rydberg U (1987) Cannabis and schizophrenia. A longitudinal study of Swedish conscripts. Lancet 2:1483-1486
3. Anguiano B, Valverde C (2001) Cold-induced increment in rat adrenal gland type II deiodinase is corticosterone dependent. Endocrine 15:87-91 (Pubitemid 32802636)
4. Barnes TR, Mutsatsa SH, Hutton SB, Watt HC, Joyce EM (2006) Comorbid substance use and age at onset of schizophrenia. Br J Psychiatry 188:237-242 (Pubitemid 43341651)
5. Black MD, Stevens RJ, Rogacki N, Featherstone RE, Senyah Y, Giardino O, Borowsky B, Stemmelin J, Cohen C, Pichat P, Arad M, Barak S, De Levie A, Weiner I, Griebel G, Varty GB (2011) AVE1625, a cannabinoid CB1 receptor antagonist, as a co-treatment with antipsychotics for schizophrenia: improvement in cognitive function and reduction of antipsychotic-side effects in rodents. Psychopharmacology (Berl) 215:149-163
6. Bortolato M, Aru GN, Frau R, Orru M, Luckey GC, Boi G, Gessa GL (2005) The CB receptor agonist WIN 55,212-2 fails to elicit disruption of prepulse inhibition of the startle in Sprague-Dawley rats. Psychopharmacology (Berl) 177:264-271 (Pubitemid 40137286)
7. Bortolato M, Campolongo P, Mangieri RA, Scattoni ML, Frau R, Trezza V,LaRanaG,RussoR, CalignanoA,Gessa GL, Cuomo V, Piomelli D (2006a) Anxiolytic-like properties of the anandamide transport inhibitor AM404. Neuropsychopharmacology 31:2652-2659 (Pubitemid 44764162)
8. Bortolato M, Frau R, Orru M, Casti A, Aru GN, Fa M, Manunta M, Usai A, Mereu G, Gessa GL (2006b) Prenatal exposure to a cannabinoid receptor agonist does not affect sensorimotor gating in rats. Eur J Pharmacol 531:166-170 (Pubitemid 43202230)
9. Braff D, Stone C, Callaway E, Geyer M, Glick I, Bali L (1978) Prestimulus effects on human startle reflex in normals and schizophrenics. Psychophysiology 15:339-343 (Pubitemid 9016401)
10. Brown TT, Dobs AS (2002) Endocrine effects of marijuana. J Clin Pharmacol 42:90S-96S (Pubitemid 35205051)
11. Buwalda B, de Boer SF, Van Kalkeren AA, Koolhaas JM (1997) Physiological and behavioral effects of chronic intracerebroven-tricular infusion of corticotropin-releasing factor in the rat. Psychoneuroendocrinology 22:297-309 (Pubitemid 27373605)
12. Cheer JF, Wassum KM, Heien ML, Phillips PE, Wightman RM (2004) Cannabinoids enhance subsecond dopamine release in the nucleus accumbens of awake rats. J Neurosci 24:4393-4400 (Pubitemid 38608150)
13. Compton DR, Aceto MD, Lowe J, Martin BR (1996) In vivo characterization of a specific cannabinoid receptor antagonist (SR141716A): inhibition of delta 9-tetrahydrocannabinol-induced responses and apparent agonist activity. J Pharmacol Exp Ther 277:586-594 (Pubitemid 27168965)
14. Corchero J, Fuentes JA, Manzanares J (1999) Chronic treatment with CP-55,940 regulates corticotropin releasing factor and proopio-melanocortin gene expression in the hypothalamus and pituitary gland of the rat. Life Sci 64:905-911 (Pubitemid 29130569)
15. Curzon P, Decker MW (1998) Effects of phencyclidine (PCP) and (+) MK-801 on sensorimotor gating in CD-1 mice. Prog Neuro-psychopharmacol Biol Psychiatry 22:129-146 (Pubitemid 28096433)
16. Czyrak A, Mackowiak M, Chocyk A, Fijal K, Gadek-Michalska A, Wedzony K (2003) 8-OHDPAT-induced disruption of prepulse inhibition in rats is attenuated by prolonged corticosterone treatment. Neuropsychopharmacology 28:1300-1310 (Pubitemid 41070900)
17. Dean B, Bradbury R, Copolov DL (2003) Cannabis-sensitive dopaminergic markers in postmortem central nervous system: changes in schizophrenia. Biol Psychiatry 53:585-592 (Pubitemid 36385060)
18. Fregly MJ (1960) Interaction of adrenals and thyroid in maintenance of body temperature of rats exposed to cold. Am J Physiol 199:437-444
19. Frisher M, Crome I, Macleod J, Millson D, Croft P (2005) Substance misuse and psychiatric illness: prospective observational study using the general practice research database. J Epidemiol Community Health 59:847-850 (Pubitemid 41360908)
20. Fritzsche M (2001) Are cannabinoid receptor knockout mice animal models for schizophrenia? Med Hypotheses 56:638-643
21. Gallistel CR, Freyd G (1987) Quantitative determination of the effects of catecholaminergic agonists and antagonists on the rewarding efficacy of brain stimulation. Pharmacol Biochem Behav 26:731-741
22. Gonzalez S, Bisogno T, Wenger T, Manzanares J, Milone A, Berrendero F, Di Marzo V, Ramos JA, Fernandez-Ruiz JJ (2000) Sex steroid influence on cannabinoid CB(1) receptor mRNA and endocannabinoid levels in the anterior pituitary gland. Biochem Biophys Res Commun 270:260-266 (Pubitemid 30440425)
23. Gonzalez S, Manzanares J, Berrendero F, Wenger T, Corchero J, Bisogno T, Romero J, Fuentes JA, Di Marzo V, Ramos JA, Fernandez-Ruiz J (1999) Identification of endocannabinoids and cannabinoid CB(1) receptor mRNA in the pituitary gland. Neuroendocrinology 70:137-145 (Pubitemid 29385394)
24. Green MF, Satz P, Smith C, Nelson L (1989) Is there atypical handedness in schizophrenia? J Abnorm Psychol 98:57-61
25. Grillon C (2002) Startle reactivity and anxiety disorders: aversive conditioning, context, and neurobiology. Biol Psychiatry 52:958-975 (Pubitemid 35356354)
26. Gupta S, Hendricks S, Kenkel AM, Bhatia SC, Haffke EA (1996) Relapse in schizophrenia: is there a relationship to substance abuse? Schizophr Res 20:153-156 (Pubitemid 26387513)
27. Hall W, Solowij N (1997) Long-term cannabis use and mental health. Br J Psychiatry 171:107-108 (Pubitemid 27345139)
28. Healy DG, Harkin A, Cryan JF, Kelly JP, Leonard BE (1999) Metyrapone displays antidepressant-like properties in preclinical paradigms. Psychopharmacology (Berl) 145:303-308 (Pubitemid 29393480)
29. Hince DA, Martin-Iverson MT (2005) Differences in prepulse inhibition (PPI) between Wistar and Sprague-Dawley rats clarified by a new method of PPI standardization. Behav Neurosci 119:66-77 (Pubitemid 40279498)
30. Ingram N, Martin S, Wang JH, van der Laan S, Loiacono R, van den Buuse M (2005) Interaction of corticosterone and nicotine in regulation of prepulse inhibition in mice. Neuropharmacology 48:80-92 (Pubitemid 40022918)
31. Jablensky A, McGrath J, Herrman H, Castle C, Gureje O, Morgan V (1999) National Survey of Mental Health and Wellbeing Report 4. People living with psychotic illness: an Australian study 1997-98. IN. National Mental Health Strategy, Australia: 103
32. Johnson KM, Dewey WL, Ritter KS, Beckner JS (1978) Cannabinoid effects on plasma corticosterone and uptake of 3H-corticosterone by mouse brain. Eur J Pharmacol 47:303-310 (Pubitemid 8269445)
33. Jones P, Murray RM (1991) The genetics of schizophrenia is the genetics of neurodevelopment. Br J Psychiatry 158:615-623
34. Kedzior KK, Martin-Iverson MT (2006) Chronic cannabis use is associated with attention-modulated reduction in prepulse inhibition of the startle reflex in healthy humans. J Psychopharmacol 20:471-484 (Pubitemid 43875177)
35. Kedzior KK, Martin-Iverson MT (2007) Attention-dependent reduction in prepulse inhibition of the startle reflex in cannabis users and schizophrenia patients-a pilot study. Eur J Pharmacol 560:176-182 (Pubitemid 46341313)
36. Long LE, Malone DT, Taylor DA (2006) Cannabidiol reverses MK-801-induced disruption of prepulse inhibition in mice. Neuro-psychopharmacology 31:795-803
37. Mansbach RS, Geyer MA, Braff DL (1988) Dopaminergic stimulation disrupts sensorimotor gating in the rat. Psychopharmacology (Berl) 94:507-514 (Pubitemid 18087401)
38. Mansbach RS, Rovetti CC, Winston EN, Lowe JA 3rd (1996) Effects of the cannabinoid CB1 receptor antagonist SR141716A on the behavior of pigeons and rats. Psychopharmacology (Berl) 124:315-322 (Pubitemid 26149916)
39. Manzanares J, Corchero J, Fuentes JA (1999) Opioid and cannabinoid receptor-mediated regulation of the increase in adrenocorticotro-pin hormone and corticosterone plasma concentrations induced by central administration of delta(9)-tetrahydrocannabinol in rats. Brain Res 839:173-179 (Pubitemid 29389804)
40. Martin-Calderon JL, Munoz RM, Villanua MA, del Arco I, Moreno JL, de Fonseca FR, Navarro M (1998) Characterization of the acute endocrine actions of (-)-11-hydroxy-delta8-tetrahydrocan-nabinol-dimethylheptyl (HU-210), a potent synthetic cannabinoid in rats. Eur J Pharmacol 344:77-86 (Pubitemid 28143951)
41. Martin-Iverson MT, Stevenson KN (2005) Apomorphine effects on emotional modulation of the startle reflex in rats. Psychopharma-cology (Berl) 181:60-70 (Pubitemid 41440916)
42. Martin RS, Secchi RL, Sung E, Lemaire M, Bonhaus DW, Hedley LR, Lowe DA (2003) Effects of cannabinoid receptor ligands on psychosis-relevant behavior models in the rat. Psychopharmacology (Berl) 165:128-135 (Pubitemid 36056989)
43. Meloni EG, Gerety LP, Knoll AT, Cohen BM, Carlezon WA Jr (2006) Behavioral and anatomical interactions between dopamine and corticotropin- releasing factor in the rat. J Neurosci 26:3855-3863
44. Miller AS, Sanudo-Pena MC, Walker JM (1998) Ipsilateral turning behavior induced by unilateral microinjections of a cannabinoid into the rat subthalamic nucleus. Brain Res 793:7-11 (Pubitemid 28294067)
45. Moore TH, Zammit S, Lingford-Hughes A, Barnes TR, Jones PB, Burke M, Lewis G (2007) Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 370:319-328 (Pubitemid 47094993)
46. Murphy LL, Munoz RM, Adrian BA, Villanua MA (1998) Function of cannabinoid receptors in the neuroendocrine regulation of hormone secretion. Neurobiol Dis 5:432-446 (Pubitemid 29075843)
47. Murray RM, Jones P, O'Callaghan E (1991) Fetal brain development and later schizophrenia. CIBA Found Symp 156:155-163, discussion 163-70
48. Nagai H, Egashira N, Sano K, Ogata A, Mizuki A, Mishima K, Iwasaki K, Shoyama Y, Nishimura R, Fujiwara M (2006) Antipsychotics improve Delta9-tetrahydrocannabinol-induced impairment of the prepulse inhibition of the startle reflex in mice. Pharmacol Biochem Behav 84:330-336 (Pubitemid 44107489)
49. Piazza PV, Rouge-Pont F, Deroche V, Maccari S, Simon H, Le Moal M (1996) Glucocorticoids have state-dependent stimulant effects on the mesencephalic dopaminergic transmission. Proc Natl Acad Sci U S A 93:8716-8720 (Pubitemid 26269626)
50. Pryce CR, Bettschen D, Bahr NI, Feldon J (2001) Comparison of the effects of infant handling, isolation, and nonhandling on acoustic startle, prepulse inhibition, locomotion, and HPA activity in the adult rat. Behav Neurosci 115:71-83 (Pubitemid 32185152)
51. Quednow BB, Kuhn KU, Hoenig K, Maier W, Wagner M (2004) Prepulse inhibition and habituation of acoustic startle response in male MDMA ('ecstasy') users, cannabis users, and healthy controls. Neuropsychopharmacology 29:982-990 (Pubitemid 38526798)
52. Rawls SM, Cabassa J, Geller EB, Adler MW (2002) CB1 receptors in the preoptic anterior hypothalamus regulate WIN 55212-2 [(4,5-dihydro-2-methyl-4(4- morpholinylmethyl)-1-(1-naphthalenyl-car-bonyl)-6H-pyrrolo[3,2,1ij] quinolin-6-one]-induced hypothermia. J Pharmacol Exp Ther 301:963-968 (Pubitemid 34595086)
53. Rawls SM, Tallarida RJ, Kon DA, Geller EB, Adler MW (2004) GABAA receptors modulate cannabinoid-evoked hypothermia. Pharmacol Biochem Behav 78:83-91 (Pubitemid 38670516)
54. Risbrough VB, Hauger RL, Roberts AL, Vale WW, Geyer MA (2004) Corticotropin-releasing factor receptors CRF1 and CRF2 exert both additive and opposing influences on defensive startle behavior. J Neurosci 24:6545-6552 (Pubitemid 38971703)
55. Schneider M, Koch M (2002) The cannabinoid agonist WIN 55,212-2 reducessensorimotor gating and recognition memory in rats. Behav Pharmacol 13:29-37 (Pubitemid 34174529)
56. Schneider M, Koch M (2003) Chronic pubertal, but not adult chronic cannabinoid treatment impairs sensorimotor gating, recognition memory, and the performance in a progressive ratio task in adult rats. Neuropsychopharmacology 28:1760-1769 (Pubitemid 41070841)
57. Scholes KE, Martin-Iverson MT (2009) Alterations to pre-pulse inhibition (PPI) in chronic cannabis users are secondary to sustained attention deficits. Psychopharmacology (Berl) 207:469-484
58. Scholes KE, Martin-Iverson MT (2010) Disturbed prepulse inhibition in patients with schizophrenia is consequential to dysfunction of selective attention. Psychophysiology 47:223-235
59. Solowij N, Michie PT (2007) Cannabis and cognitive dysfunction: parallels with endophenotypes of schizophrenia? J Psychiatry Neurosci 32:30-52
60. Stanley-Cary CC, Harris C, Martin-Iverson MT (2002) Differing effects of the cannabinoid agonist, CP 55,940, in an alcohol or Tween 80 solvent, on prepulse inhibition of the acoustic startle reflex in the rat. Behav Pharmacol 13:15-28 (Pubitemid 34176800)
61. Stevens KE, Bullock AE, Collins AC (2001) Chronic corticosterone treatment alters sensory gating in C3H mice. Pharmacol Biochem Behav 69:359-366 (Pubitemid 32758718)
62. Stoddart CW, Noonan J, Martin-Iverson MT (2008) Stimulus quality affects expression of the acoustic startle response and prepulse inhibition in mice. Behav Neurosci 122:516-526 (Pubitemid 351787831)
63. Strube MJ, Bobko P (1989) Testing hypotheses about ordinal interactions: simulations and further comments. J Appl Psychol 74:247-252
64. Swerdlow NR, Eastvold A, Karban B, Ploum Y, Stephany N, Geyer MA, Cadenhead K, Auerbach PP (2002) Dopamine agonist effects on startle and sensorimotor gating in normal male subjects: time course studies. Psychopharmacology (Berl) 161:189-201 (Pubitemid 34492664)
65. Swerdlow NR, Stephany N, Wasserman LC, Talledo J, Shoemaker J, Auerbach PP (2003) Amphetamine effects on prepulse inhibition across-species: replication and parametric extension. Neuropsychopharmacology 28:640-650
66. van den Buuse M, Morris M, Chavez C, Martin S, Wang J (2004) Effect of adrenalectomy and corticosterone replacement on prepulse inhibition and locomotor activity in mice. Br J Pharmacol 142:543-550 (Pubitemid 38869868)
67. van Os J, Bak M, Hanssen M, Bijl RV, de Graaf R, Verdoux H (2002) Cannabis use and psychosis: a longitudinal population-based study. Am J Epidemiol 156:319-327 (Pubitemid 34857999)
68. Verdoux H, Sorbara F, Gindre C, Swendsen JD, van Os J (2003) Cannabis use and dimensions of psychosis in a nonclinical population of female subjects. Schizophr Res 59:77-84 (Pubitemid 35284497)
69. Waddington JL, Torrey EF, Crow TJ, Hirsch SR (1991) Schizophrenia, neurodevelopment, and disease. The Fifth Biannual Winter Workshop on Schizophrenia, Badgastein, Austria, January 28 to February 3, 1990. Arch Gen Psychiatry 48:271-273
70. Weidenfeld J, Feldman S, Mechoulam R (1994) Effect of the brain constituent anandamide, a cannabinoid receptor agonist, on the hypothalamo-pituitary-adrenal axis in the rat. Neuroendocrinology 59:110-112 (Pubitemid 24032705)
71. Weiser M, Noy S (2005) Interpreting the association between cannabis use and increased risk for schizophrenia. Dialogues Clin Neurosci 7:81-85 (Pubitemid 40545559)
72. Wenger T, Jamali KA, Juaneda C, Leonardelli J, Tramu G (1997) Arachidonyl ethanolamide (anandamide) activates the parvocel-lular part of hypothalamic paraventricular nucleus. Biochem Biophys Res Commun 237:724-728 (Pubitemid 27434755)
73. Zammit S, Allebeck P, Andreasson S, Lundberg I, Lewis G (2002) Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study. BMJ 325:1199
74. Zuardi AW, Crippa JA, Hallak JE, Moreira FA, Guimaraes FS (2006) Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug. Braz J Med Biol Res 39:421-429